Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 42.37M shares outstanding
USPetros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease.
The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Joshua N. Silverman
Executive Chairman of the Board
Fady Boctor
President & Chief Commercial Officer
Robert Weinstein
Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer
Employees
18
Country
US
Sector
Healthcare
Website
petrospharma.com
Loading congressional disclosures…
based on 42.37M shares outstanding
US30d Avg
154.77K
60d Avg
129.55K
90d Avg
131.56K
